Content Validity and Scoring of Intrauterine System Daily Bleeding Diary (IUS-DBD) for Women Using Ius for Contraception
Author(s)
Wichmann K1, Aldhouse N2, Haberland C1, Filonenko A1, Staccuneddu M3, Al-Zubeidi T4, Kitchen H2
1Bayer AG, Berlin, BE, Germany, 2DRG (part of Clarivate), Manchester, UK, 3DRG (part of Clarivate), Nashville, TN, USA, 4DRG (part of Clarivate), Bicester, OXF, UK
The IUS Daily Bleeding Diary (IUS-DBD) is a single-item patient-reported outcome (PRO) measure with a 5-point Likert response scale and a 24-hour recall period, designed to evaluate the intensity and frequency of uterine bleeding. In accordance with United States (US) Food and Drug Administration (FDA) PRO Guidance for Industry 2009 requirements, this study evaluated the content validity (relevance, appropriateness, and understandability) and scoring of the IUS-DBD in a sample of women using IUS for contraception.
METHODS This was a non-interventional, qualitative interview study. Participants were identified by clinicians in the US; women were eligible if they had used IUS contraception for 2–6 months and had experienced bleeding during this time or had the IUS removed due to bleeding. Interviews utilized a semi-structured interview guide with concept elicitation and cognitive debriefing methodology to evaluate the content validity of the IUS-DBD. Hypothetical bleeding profiles were assessed to explore clinically meaningful differences . Transcripts were analysed using framework analysis techniques in ATLAS.ti v7. RESULTS Twenty women were interviewed. Participants (n=16/20, 80%) reported experiencing initial bothersome bleeding/spotting following IUS insertion and stated that fewer days of bleeding/spotting during the initial 3 months would be an important and meaningful improvement (n=18/18, 100%). Participants (n=20/20, 100%) interpreted the meaning of the IUS-DBD correctly (n=20/20, 100%) and found it easy to understand (n=18/19, 95%). Most correctly interpreted the recall period (n=17/20, 85%) and found the response options to be appropriate, distinct and usable (n=17/20, 85%). Based on hypothetical bleeding profiles, participants perceived a 10% reduction in days of bleeding/spotting per 30 days to be minimally improved (20%-42% participants), a 30% reduction to be minimally/much improved (>85% participants), and a 50% reduction to be much/very much improved (>75% participants). CONCLUSIONSThe IUS-DBD is a content valid PRO to evaluate uterine bleeding in clinical studies with women using IUS for contraception.
Conference/Value in Health Info
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PIH36
Topic
Patient-Centered Research
Topic Subcategory
Instrument Development, Validation, & Translation, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Reproductive and Sexual Health